Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

BioSentinel Pharmaceuticals LLC
Profile last edited on: 4/8/16      CAGE: 4G7L1      UEI:

Business Identifier: development of innovative tools and reagents for the study of botulinum neurotoxin (BoNT).
Year Founded
2007
First Award
2009
Latest Award
2013
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

510 Charmany Drive Suite 260
Madison, WI 53719
   (608) 441-8174
   info@biosentinelpharma.com
   www.biosentinelpharma.com
Location: Single
Congr. District: 02
County: Dane

Public Profile

BioSentinel Inc is a biopharmaceutical company developng novel detection systems, high specificity and sensitivity portable, and biosensor devices. The company is focused on the discovery of antagonists for prevention of bioterrorism by use of botulinum neurotoxins (BoNTs). The company is developing a range of assays, devices, and sensors for the detection and prevention of BoNT toxins.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
2
Conversion Rate
66.67%
Phase I Dollars
$661,334
Phase II Dollars
$2,076,701
Total Awarded
$2,738,035

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2017 2 NSF $1,176,313
Project Title: De novo assays for detection of the proteolytic activity in botulinum neurotoxin-based pharmaceuticals
2013 2 NIH $1,959,360
Project Title: A Cell-Based Assay For Botulinum Neurotoxin Detection And Development
2011 1 NIH $212,310
Project Title: Validation Of A Cell-Based Assay For Bont/A Detection Against The Mouse Bioassay

Key People / Management

  Michael T Beck -- Director, Molecular Biology

  Mark Dunning -- Director, Cell Biology

  Timothy Piazza -- Director, Cell Biology

  Ward C Tucker -- Director, Research & Development

  Füsûn N Zeytin -- President; Chief Executive Officer

Company News

There are no news available.